stella
beta
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients — Stella
Home
/
Type 2 Diabetic Patients
/
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
View on ClinicalTrials.gov
Recruiting
Back to Type 2 Diabetic Patients trials
Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(16 sites)
China
Pinggu District Hospital, Beijing, Beijing Municipality
Capital Medical University Beijing Anzhen Hospital, Beijing, Beijing Municipality
Emergency General Hospital, Beijing, Beijing Municipality
Peking University Shougang Hospital, Beijing, Beijing Municipality
Southern Medical University Nanfang Hospital, Guangzhou, Guangdong
Harbin Medical University Second Hospital, Harbin, Heilongjiang
Southeast University Zhongda Hospital, Nanjing, Jiangsu
Xuzhou Medical University Affiliated Hospital, Xuzhou, Jiangsu
China-Japan Union Hospital of Jilin University, Changchun, Jilin
Jilin University Second Hospital, Changchun, Jilin
Xi'an Jiaotong University Second Hospital, Xi'an, Shaanxi
Southwest Medical University Affiliated Hospital, Luzhou, Sichuan
Peking University Binhai Hospital, Tianjin, Tianjin Municipality
First Hospital of Peking University, Beijing
Heilongjiang provincial hospital, Harbin
Henan People's Hospital, Zhengzhou